NeuroSense Therapeutics (NASDAQ:NRSN) Shares Down 6.6% – Here’s What Happened

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) were down 6.6% on Monday . The company traded as low as $0.6701 and last traded at $0.6870. Approximately 297,758 shares traded hands during trading, an increase of 140% from the average daily volume of 123,877 shares. The stock had previously closed at $0.7352.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on NRSN shares. D. Boral Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of NeuroSense Therapeutics in a research report on Wednesday, April 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research note on Friday, May 8th. Finally, Roth Mkm began coverage on NeuroSense Therapeutics in a research note on Tuesday, March 10th. They set a “buy” rating and a $3.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $8.50.

NeuroSense Therapeutics Trading Up 0.9%

The firm has a 50 day moving average of $0.78 and a 200-day moving average of $0.86. The company has a market cap of $22.95 million, a P/E ratio of -1.31 and a beta of 1.56.

Insider Activity at NeuroSense Therapeutics

In other NeuroSense Therapeutics news, CFO Or Eisenberg bought 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were bought at an average price of $0.80 per share, with a total value of $200,000.00. Following the purchase, the chief financial officer owned 1,504,050 shares of the company’s stock, valued at $1,203,240. This trade represents a 19.94% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Alon Ben-Noon bought 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were acquired at an average cost of $0.80 per share, for a total transaction of $200,000.00. Following the purchase, the chief executive officer directly owned 4,534,233 shares in the company, valued at $3,627,386.40. This trade represents a 5.84% increase in their position. The SEC filing for this purchase provides additional information. 27.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On NeuroSense Therapeutics

Several large investors have recently modified their holdings of NRSN. Two Sigma Investments LP bought a new position in shares of NeuroSense Therapeutics during the 3rd quarter valued at approximately $26,000. Jane Street Group LLC bought a new position in shares of NeuroSense Therapeutics during the 2nd quarter valued at approximately $54,000. Yorkville Advisors Global LP bought a new position in shares of NeuroSense Therapeutics during the 4th quarter valued at approximately $77,000. Finally, Squarepoint Ops LLC increased its position in shares of NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares during the last quarter. Institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.